Search Results

Smith+Nephew, the global medical technology company, announced they have entered into a Master Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research.

Virpax Pharmaceuticals Announces Preliminary Results of Probudur TM Pilot Study with the U.S. Army Institute of Surgical Research.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that novel, twice daily, oral opaganib[1], delivered a statistically significant increase in survival time when given at 150 mg/kg twice a day (BID) in a United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in vivo Ebola virus study, making it the first host-directed molecule to show activity in Ebola virus disease.

Shionogi & Co., Ltd. announced the company is responding to the urgent global need for additional antimicrobial research and development by establishing its first discovery laboratory in the U.S., in San Diego, California.

RION, a leading clinical-stage regenerative medicine company, announced that it will collaborate with Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense on a $2.4M grant awarded from the Department of Defense.

Virpax ® Pharmaceuticals, Inc. today announced that the cooperative research and development agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) to evaluate Virpax’s Probudur™, an injectable long-acting liposomal bupivacaine formulation that is injected at the wound site, has been extended to September of 2024.

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”) today announces that the company will be utilizing the preclinical services program offered by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate RLS-0071 as a medical countermeasure for Acute Radiation Syndrome (ARS).

Inhalon Biopharma announced that it has been awarded a $5.7 million contract by the U.S Army Medical Research and Development Command to support a U.S. Army Military Performance Advancement Initiative project to develop new treatments for COVID-19 and other SARS infections.

The Bill & Melinda Gates Medical Research Institute announced the appointment of Patrice Matchaba, MD, as Chief Executive Officer, starting June 10, 2024.